BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22640166)

  • 1. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome.
    Tjensvoll K; Oltedal S; Heikkilä R; Kvaløy JT; Gilje B; Reuben JM; Smaaland R; Nordgård O
    BMC Cancer; 2012 May; 12():190. PubMed ID: 22640166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients.
    Tjensvoll K; Oltedal S; Farmen RK; Shammas FV; Heikkilä R; Kvaløy JT; Gilje B; Smaaland R; Nordgård O
    Clin Breast Cancer; 2010 Oct; 10(5):378-84. PubMed ID: 20920982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.
    Synnestvedt M; Borgen E; Wist E; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Schirmer C; Nesland JM; Naume B
    BMC Cancer; 2012 Dec; 12():616. PubMed ID: 23259667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.
    Mathiesen RR; Borgen E; Renolen A; Løkkevik E; Nesland JM; Anker G; Ostenstad B; Lundgren S; Risberg T; Mjaaland I; Kvalheim G; Lønning PE; Naume B
    Breast Cancer Res; 2012 Aug; 14(4):R117. PubMed ID: 22889108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
    Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
    Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A small subgroup of operable breast cancer patients with poor prognosis identified by quantitative real-time RT-PCR detection of mammaglobin A and trefoil factor 1 mRNA expression in bone marrow.
    Tjensvoll K; Gilje B; Oltedal S; Shammas VF; Kvaløy JT; Heikkilä R; Nordgård O
    Breast Cancer Res Treat; 2009 Jul; 116(2):329-38. PubMed ID: 18846421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
    Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
    J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of molecular and immunocytochemical methods for detection of disseminated tumor cells in bone marrow from early breast cancer patients.
    Gilje B; Nordgård O; Tjensvoll K; Borgen E; Synnestvedt M; Smaaland R; Naume B
    BMC Cancer; 2014 Jul; 14():514. PubMed ID: 25023626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.
    Falck AK; Bendahl PO; Ingvar C; Isola J; Jönsson PE; Lindblom P; Lövgren K; Rennstam K; Fernö M; Rydén L
    BMC Cancer; 2012 Sep; 12():403. PubMed ID: 22963449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
    Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
    Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients.
    Farmen RK; Nordgård O; Gilje B; Shammas FV; Kvaløy JT; Oltedal S; Heikkilä R
    Breast Cancer Res Treat; 2008 Mar; 108(2):251-8. PubMed ID: 17492378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
    Pillai SG; Li S; Siddappa CM; Ellis MJ; Watson MA; Aft R
    Breast Cancer Res; 2018 Jan; 20(1):2. PubMed ID: 29291741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis.
    Hartkopf AD; Brucker SY; Taran FA; Harbeck N; von Au A; Naume B; Pierga JY; Hoffmann O; Beckmann MW; Rydén L; Fehm T; Aft R; Solà M; Walter V; Rack B; Schuetz F; Borgen E; Ta MH; Bittner AK; Fasching PA; Fernö M; Krawczyk N; Weilbaecher K; Margelí M; Hahn M; Jueckstock J; Domschke C; Bidard FC; Kasimir-Bauer S; Schoenfisch B; Kurt AG; Wallwiener M; Gebauer G; Klein CA; Wallwiener D; Janni W; Pantel K
    Eur J Cancer; 2021 Sep; 154():128-137. PubMed ID: 34265505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse.
    Hartkopf AD; Wallwiener M; Fehm TN; Hahn M; Walter CB; Gruber I; Brucker SY; Taran FA
    Ann Oncol; 2015 Jun; 26(6):1155-1160. PubMed ID: 25791636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
    Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M
    Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients.
    Molloy TJ; Bosma AJ; Baumbusch LO; Synnestvedt M; Borgen E; Russnes HG; Schlichting E; van't Veer LJ; Naume B
    Breast Cancer Res; 2011 Jun; 13(3):R61. PubMed ID: 21672237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients.
    Tjensvoll K; Nordgård O; Skjæveland M; Oltedal S; Janssen EAM; Gilje B
    BMC Cancer; 2019 Nov; 19(1):1131. PubMed ID: 31752747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse.
    Siddappa CM; Pillai SG; Snider J; Alldredge P; Trinkaus K; Watson MA; Aft R
    Breast Cancer Res Treat; 2019 Nov; 178(2):317-325. PubMed ID: 31432366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients.
    Borgen E; Rypdal MC; Sosa MS; Renolen A; Schlichting E; Lønning PE; Synnestvedt M; Aguirre-Ghiso JA; Naume B
    Breast Cancer Res; 2018 Oct; 20(1):120. PubMed ID: 30322396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.
    Hoffmann O; Aktas B; Goldnau C; Heubner M; Oberhoff C; Kimmig R; Kasimir-Bauer S
    Anticancer Res; 2011 Oct; 31(10):3623-8. PubMed ID: 21965788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.